These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1357542)

  • 21. Comparative effects of receptor inactivation, 17 beta-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro.
    Meller E; Puza T; Diamond J; Lieu HD; Bohmaker K
    J Pharmacol Exp Ther; 1992 Nov; 263(2):462-9. PubMed ID: 1359107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P; Olianas MC; Gessa GL
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors.
    Roberts DJ; Lin H; Strange PG
    Biochem Pharmacol; 2004 May; 67(9):1657-65. PubMed ID: 15081865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D; Salah RS; Galloway MP
    Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increases in guanine nucleotide binding to striatal G proteins is associated with dopamine receptor supersensitivity.
    Butkerait P; Wang HY; Friedman E
    J Pharmacol Exp Ther; 1994 Oct; 271(1):422-8. PubMed ID: 7965743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric dopamine D2/angiotensin AT1 receptors: role of the length of third intracellular loop of D2 receptors in conferring specificity of receptor binding and G-protein coupling.
    Chen H; Zhang YY; Han QD
    Zhongguo Yao Li Xue Bao; 1997 May; 18(3):209-13. PubMed ID: 10072934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel (R)-2-amino-5-fluorotetralins: dopaminergic antagonists and inverse agonists.
    Malmberg A; Höök BB; Johansson AM; Hacksell U
    J Med Chem; 1996 Oct; 39(22):4421-9. PubMed ID: 8893836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells.
    Kanterman RY; Mahan LC; Briley EM; Monsma FJ; Sibley DR; Axelrod J; Felder CC
    Mol Pharmacol; 1991 Mar; 39(3):364-9. PubMed ID: 1848657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.
    Selley DE; Liu Q; Childers SR
    J Pharmacol Exp Ther; 1998 May; 285(2):496-505. PubMed ID: 9580589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L; Gerlach J
    Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides.
    Malmberg A; Mohell N
    J Pharmacol Exp Ther; 1995 Aug; 274(2):790-7. PubMed ID: 7636742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro receptor binding characteristics of the new dopamine D2 antagonist [125I]NCQ-298: methodological considerations of high affinity binding.
    Jerning E; Malmberg A; Mohell N
    J Recept Signal Transduct Res; 1995; 15(1-4):503-15. PubMed ID: 8903960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics.
    Kara E; Lin H; Strange PG
    J Neurochem; 2010 Mar; 112(6):1442-53. PubMed ID: 20050980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine receptors labelled by [3H]quinpirole.
    Seeman P; Schaus JM
    Eur J Pharmacol; 1991 Oct; 203(1):105-9. PubMed ID: 1686763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the functional activity of dopamine ligands at human recombinant dopamine D4 receptors.
    Chabert C; Cavegn C; Bernard A; Mills A
    J Neurochem; 1994 Jul; 63(1):62-5. PubMed ID: 7911513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.
    Kreiss DS; Bergstrom DA; Gonzalez AM; Huang KX; Sibley DR; Walters JR
    Eur J Pharmacol; 1995 Apr; 277(2-3):209-14. PubMed ID: 7493610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre- and postsynaptic dopaminergic activities of U-86170F.
    Lahti RA; Evans DL; Figur LM; Huff RM; Moon MW
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Nov; 344(5):509-13. PubMed ID: 1687420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.